Prognostic and predictive markers for personalized adjuvant therapy for non-small-cell lung cancer patients.
Adjuvant chemotherapy following surgical resection in non-small-cell lung cancer patients with large tumors (>4 cm) or tumors with lymph node metastases has emerged as a standard of care. The benefits of adjuvant chemotherapy are modest, with a 5-year survival improvement of only 5-10%. In addition, survival rates of 25% or greater with surgery alone suggest that some patients do not need adjuvant therapy. Therefore, there is a need to develop prognostic and predictive markers to identify patients in need of adjuvant therapy and the patients likely to benefit from such therapy. Many factors have been evaluated for this purpose and some of these factors, such as visceral pleural invasion, can influence the decision to use adjuvant chemotherapy. However, most of the available data are retrospective, which limits the utility of these markers in current practice. Ongoing trials are evaluating many promising markers and may guide adjuvant therapy in the future.